|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Elmore JG, Armstrong K, Lehman CD and
Fletcher SW: Screening for breast cancer. JAMA. 293:1245–1256.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tabár L, Vitak B, Chen HH, Duffy SW, Yen
MF, Chiang CF, Krusemo UB, Tot T and Smith RA: The Swedish
Two-County Trial twenty years later. Updated mortality results and
new insights from long-term follow-up. Radiol Clin North Am.
38:625–651. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soerjomataram I, Louwman MW, Ribot JG,
Roukema JA and Coebergh JW: An overview of prognostic factors for
long-term survivors of breast cancer. Breast Cancer Res Treat.
107:309–330. 2008. View Article : Google Scholar :
|
|
5
|
Foulkes WD, Reis-Filho JS and Narod SA:
Tumor size and survival in breast cancer - a reappraisal. Nat Rev
Clin Oncol. 7:348–353. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Anan K, Mitsuyama S, Koga K, Tanabe R,
Saimura M, Tanabe Y, Watanabe M, Suehara N, Matsunaga H, Nishihara
K, et al: Disparities in the survival improvement of recurrent
breast cancer. Breast Cancer. 17:48–55. 2010. View Article : Google Scholar
|
|
7
|
Nguyen DX, Bos PD and Massagué J:
Metastasis: From dissemination to organ-specific colonization. Nat
Rev Cancer. 9:274–284. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morgan BP, Marchbank KJ, Longhi MP, Harris
CL and Gallimore AM: Complement: Central to innate immunity and
bridging to adaptive responses. Immunol Lett. 97:171–179. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ricklin D, Hajishengallis G, Yang K and
Lambris JD: Complement: A key system for immune surveillance and
homeo-stasis. Nat Immunol. 11:785–797. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matsumoto M, Takeda J, Inoue N, Hara T,
Hatanaka M, Takahashi K, Nagasawa S, Akedo H and Seya T: A novel
protein that participates in nonself discrimination of malignant
cells by homologous complement. Nat Med. 3:1266–1270. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dunkelberger JR and Song WC: Complement
and its role in innate and adaptive immune responses. Cell Res.
20:34–50. 2010. View Article : Google Scholar
|
|
13
|
Zhou X, Hu W and Qin X: The role of
complement in the mechanism of action of rituximab for B-cell
lymphoma: Implications for therapy. Oncologist. 13:954–966. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fishelson Z, Donin N, Zell S, Schultz S
and Kirschfink M: Obstacles to cancer immunotherapy: Expression of
membrane complement regulatory proteins (mCRPs) in tumors. Mol
Immunol. 40:109–123. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Davies A and Lachmann PJ: Membrane defence
against complement lysis: The structure and biological properties
of CD59. Immunol Res. 12:258–275. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li B, Lin H, Fan J, Lan J, Zhong Y, Yang
Y, Li H and Wang Z: CD59 is overexpressed in human lung cancer and
regulates apoptosis of human lung cancer cells. Int J Oncol.
43:850–858. 2013.PubMed/NCBI
|
|
17
|
Hu W, Ge X, You T, Xu T, Zhang J, Wu G,
Peng Z, Chorev M, Aktas BH, Halperin JA, et al: Human CD59
inhibitor sensitizes rituximab-resistant lymphoma cells to
complement-mediated cytolysis. Cancer Res. 71:2298–2307. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rus HG, Niculescu FI and Shin ML: Role of
the C5b-9 complement complex in cell cycle and apoptosis. Immunol
Rev. 180:49–55. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Madjd Z, Pinder SE, Paish C, Ellis IO,
Carmichael J and Durrant LG: Loss of CD59 expression in breast
tumours correlates with poor survival. J Pathol. 200:633–639. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li B, Chu X, Gao M and Xu Y: The effects
of CD59 gene as a target gene on breast cancer cells. Cell Immunol.
272:61–70. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Terp MG, Lund RR, Jensen ON, Leth-Larsen R
and Ditzel HJ: Identification of markers associated with highly
aggressive meta-static phenotypes using quantitative comparative
proteomics. Cancer Genomics Proteomics. 9:265–273. 2012.PubMed/NCBI
|
|
22
|
Maio M, Brasoveanu LI, Coral S, Sigalotti
L, Lamaj E, Gasparollo A, Visintin A, Altomonte M and Fonsatti E:
Structure, distribution, and functional role of protectin (CD59) in
complement-susceptibility and in immunotherapy of human
malignancies (Review). Int J Oncol. 13:305–318. 1998.PubMed/NCBI
|
|
23
|
Liu ZB, Hou YF, Min-Dong, Di GH, Wu J,
Shen ZZ and Shao ZM: PA-MSHA inhibits proliferation and induces
apoptosis through the up-regulation and activation of caspases in
the human breast cancer cell lines. J Cell Biochem. 108:195–206.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Du Y, Teng X, Wang N, Zhang X, Chen J,
Ding P, Qiao Q, Wang Q, Zhang L, Yang C, et al: NF-κB and
enhancer-binding CREB protein scaffolded by CREB-binding protein
(CBP)/p300 proteins regulate CD59 protein expression to protect
cells from complement attack. J Biol Chem. 289:2711–2724. 2014.
View Article : Google Scholar :
|
|
25
|
Detre S, Saclani Jotti G and Dowsett M: A
‘quickscore’ method for immunohistochemical semiquantitation:
Validation for oestrogen receptor in breast carcinomas. J Clin
Pathol. 48:876–878. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Harvey JM, Clark GM, Osborne CK and Allred
DC: Estrogen receptor status by immunohistochemistry is superior to
the ligand-binding assay for predicting response to adjuvant
endocrine therapy in breast cancer. J Clin Oncol. 17:1474–1481.
1999.PubMed/NCBI
|
|
27
|
Du K and Montminy M: CREB is a regulatory
target for the protein kinase Akt/PKB. J Biol Chem.
273:32377–32379. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Choi YH, Lee SN, Aoyagi H, Yamasaki Y, Yoo
JY, Park B, Shin DM, Yoon HG and Yoon JH: The extracellular
signal-regulated kinase mitogen-activated protein kinase/ribosomal
S6 protein kinase 1 cascade phosphorylates cAMP response
element-binding protein to induce MUC5B gene expression via
D-prostanoid receptor signaling. J Biol Chem. 286:34199–34214.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Boulware MI, Weick JP, Becklund BR, Kuo
SP, Groth RD and Mermelstein PG: Estradiol activates group I and II
metabotropic glutamate receptor signaling, leading to opposing
influences on cAMP response element-binding protein. J Neurosci.
25:5066–5078. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu M, Yang YJ, Zheng H, Zhong XR, Wang Y,
Wang Z, Wang YG and Wang YP: Membrane-bound complement regulatory
proteins are prognostic factors of operable breast cancer treated
with adjuvant trastuzumab: A retrospective study. Oncol Rep.
32:2619–2627. 2014.PubMed/NCBI
|
|
31
|
Mamidi S, Cinci M, Hasmann M, Fehring V
and Kirschfink M: Lipoplex mediated silencing of membrane
regulators (CD46, CD55 and CD59) enhances complement-dependent
anti-tumor activity of trastuzumab and pertuzumab. Mol Oncol.
7:580–594. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Samatar AA and Poulikakos PI: Targeting
RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug
Discov. 13:928–942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lipp AM, Juhasz K, Paar C, Ogris C,
Eckerstorfer P, Thuenauer R, Hesse J, Nimmervoll B, Stockinger H,
Schütz GJ, et al: Lck mediates signal transmission from CD59 to the
TCR/CD3 pathway in Jurkat T cells. PLoS One. 9:e859342014.
View Article : Google Scholar : PubMed/NCBI
|
